share_log

Mangoceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Jacob D.

Mangoceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Jacob D.

Mangoceuticals | 4:持股变动声明-高管 Cohen Jacob D.
美股SEC公告 ·  06/05 17:17
Moomoo AI 已提取核心信息
Jacob D. Cohen, the Chief Executive Officer of Mangoceuticals, Inc. (MGRX), completed a significant stock transaction on June 3, 2024. Cohen was granted 800,000 shares of common stock at no cost, as per the transaction details released. Following this grant, Cohen directly holds a total of 800,000 shares in the company. The transaction, which was classified as a grant, indicates a strengthening of the CEO's stake in Mangoceuticals, potentially signaling confidence in the company's future prospects.
Jacob D. Cohen, the Chief Executive Officer of Mangoceuticals, Inc. (MGRX), completed a significant stock transaction on June 3, 2024. Cohen was granted 800,000 shares of common stock at no cost, as per the transaction details released. Following this grant, Cohen directly holds a total of 800,000 shares in the company. The transaction, which was classified as a grant, indicates a strengthening of the CEO's stake in Mangoceuticals, potentially signaling confidence in the company's future prospects.
Mangoceuticals公司的首席执行官Jacob D. Cohen(cohen)于2024年6月3日完成了一项重大的股权交易。根据公布的交易细节,Cohen免费获得了80万股普通股。在此次授予之后,Cohen直接持有公司的80万股股份。这项被归类为授予的交易表明,CEO强化了他在Mangoceuticals的持股,可能表示对该公司未来前景的信恳智能。
Mangoceuticals公司的首席执行官Jacob D. Cohen(cohen)于2024年6月3日完成了一项重大的股权交易。根据公布的交易细节,Cohen免费获得了80万股普通股。在此次授予之后,Cohen直接持有公司的80万股股份。这项被归类为授予的交易表明,CEO强化了他在Mangoceuticals的持股,可能表示对该公司未来前景的信恳智能。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息